论文部分内容阅读
目的探究与分析诺和锐30联合维格列汀治疗初诊重度2型糖尿病的临床疗效。方法选取本院自2012年12月~2013年11月收治的初诊重度2型糖尿病患者60例,将其作为临床研究对象,采取随机数字表法分为对照组和观察组,每组各30例,对照组给予诺和锐30治疗,观察组在其基础上加用维格列汀治疗,观察与对比两组患者的临床疗效。结果两组患者治疗后空腹血糖、餐后血糖、HbA1c、甘油三酯、总胆固醇、低密度脂蛋白胆固醇较治疗前显著降低,差异有统计学意义(P<0.05),观察组较对照组降低显著,P<0.05,差异具有统计学意义。结论诺和锐30联合维格列汀治疗初诊重度2型糖尿病的临床疗效显著,能够全面降低患者血糖,不良反应少,低血糖发生率低。
Objective To investigate and analyze the clinical efficacy of Novo-Rui 30 combined with Vildagliptin in the treatment of newly diagnosed severe type 2 diabetes mellitus. Methods Sixty patients with newly diagnosed type 2 diabetes in our hospital from December 2012 to November 2013 were selected and divided into control group and observation group with 30 cases in each group , The control group was treated with Novo Rui 30, the observation group was treated with Vildagliptin on the basis of the observation group, and the clinical efficacy was observed and compared between the two groups. Results After treatment, fasting blood glucose, postprandial blood glucose, HbA1c, triglyceride, total cholesterol and low density lipoprotein cholesterol in the two groups were significantly lower than those before treatment, the difference was statistically significant (P <0.05), the observation group was lower than the control group Significantly, P <0.05, the difference was statistically significant. Conclusion Novo-Rui 30 combined with Vitalogliptin in the treatment of newly diagnosed severe type 2 diabetes has a significant clinical effect, which can fully reduce the patient’s blood glucose, adverse reactions, and low incidence of hypoglycemia.